Not recruiting
Investigational
Phase 3 Study of ZIGAKIBART (BION-1301) in Adults with IgA Nephropathy
Investigational
- Substances:ZIGAKIBART
Countries:
Spain
Spain- Participants:18–64 years · 65+ years
- Substances:ZIGAKIBART
- Sponsor:Novartis Pharma AG
Back to SpainClinical trials in Sevilla – page 69
1 637 clinical trials in Sevilla, Spain across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in SpainEnsayosClinicos.es(opens in a new tab)Sevilla at a glance
1 637
clinical trials
- Research sites4
Not recruiting
Narcolepsy
Not recruitingEfficacy and Safety of E2086 in Adults with Narcolepsy: A Randomized, Double‑Blind, Placebo‑Controlled Trial
Investigational
Efficacy and Safety of E2086 in Adults with Narcolepsy: A Randomized, Double‑Blind, Placebo‑Controlled Trial
Investigational
- Disease:Narcolepsy
- Substances:–
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Sponsor:Eisai Limited
Not recruiting
Dermatomyositis+3
Not recruitingPhase 2 Study of Daxdilimab with Prednisone in Adults with Inadequately Controlled Dermatomyositis or Anti‑Synthetase Inflammatory Myositis
Registered drug
Phase 2 Study of Daxdilimab with Prednisone in Adults with Inadequately Controlled Dermatomyositis or Anti‑Synthetase Inflammatory Myositis
Registered drug
- Disease:DermatomyositisAntisynthetase syndrome+2
- Substances:DaxdilimabPrednisone
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Daxdilimab
- Sponsor:Horizon Therapeutics Ireland Designated Activity Company
Not recruiting
Chronic rhinosinusitis with nasal polyps
Not recruitingLong‑term safety and tolerability of itepekimab in adults with inadequately controlled chronic rhinosinusitis with nasal polyps: an extension study
Investigational
Long‑term safety and tolerability of itepekimab in adults with inadequately controlled chronic rhinosinusitis with nasal polyps: an extension study
Investigational
- Disease:Chronic rhinosinusitis with nasal polyps
- Substances:Itepekimab
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Itepekimab
- Sponsor:Sanofi-Aventis Recherche & Developpement
Not recruiting
Obesity
Not recruitingStudy of KAI-9531 in Adults With Obesity or Overweight and Weight-Related Health Problems Without Diabetes
Investigational
Study of KAI-9531 in Adults With Obesity or Overweight and Weight-Related Health Problems Without Diabetes
Investigational
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:HRS 9531
Not recruiting
Rheumatoid arthritis
Not recruitingBaricitinib Compared with Adalimumab and Etanercept in Patients with Rheumatoid Arthritis
Registered drugNo placebo
Baricitinib Compared with Adalimumab and Etanercept in Patients with Rheumatoid Arthritis
Registered drugNo placebo
- Disease:Rheumatoid arthritis
- Substances:AdalimumabBaricitinib+1
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Adalimumab
- Sponsor:Eli Lilly & Co.
Not recruiting
Obesity
Not recruitingA study to evaluate the efficacy and safety of zenagamtide in people with obesity
Investigational
A study to evaluate the efficacy and safety of zenagamtide in people with obesity
Investigational
- Disease:Obesity
- Substances:–
Countries:Spain
Spain- Participants:18–64 years
- Sponsor:Novo Nordisk A/S
Not recruiting
Colitis ulcerative+1
Not recruitingA study to evaluate the long-term safety and effectiveness of balinatunfib in adults with Crohn's disease or ulcerative colitis
Investigational
A study to evaluate the long-term safety and effectiveness of balinatunfib in adults with Crohn's disease or ulcerative colitis
Investigational
- Disease:Colitis ulcerativeCrohn's disease
- Substances:–
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Sponsor:Sanofi-Aventis Recherche & Developpement
Not recruiting
Squamous cell carcinoma of head and neck
Not recruitingEfficacy Comparison of Zanzalintinib (XL092) and Pembrolizumab Versus Pembrolizumab Monotherapy in PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Registered drugNo placebo
Efficacy Comparison of Zanzalintinib (XL092) and Pembrolizumab Versus Pembrolizumab Monotherapy in PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Registered drugNo placebo
- Disease:Squamous cell carcinoma of head and neck
- Substances:PembrolizumabN-(4-Fluorophenyl)-N-(4-((7-Methoxy-6-(Methylcarbamoyl)Quinolin-4- Yl)Oxy)Phenyl)Cyclopropane-1,1-Dicarboxamide
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Pembrolizumab
- Sponsor:Exelixis Inc.
Not recruiting
Small cell lung cancer
Not recruitingEvaluation of HLX10 Combined with Chemotherapy and Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase III Randomized, Double-Blind Study
InvestigationalNo placebo
Evaluation of HLX10 Combined with Chemotherapy and Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase III Randomized, Double-Blind Study
InvestigationalNo placebo
- Disease:Small cell lung cancer
- Substances:–
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Sponsor:Shanghai Henlius Biotech Inc.
Not recruiting
Colorectal cancer metastatic
Not recruitingPhase III Study Comparing FOLFOX Plus Panitumumab Followed by FOLFIRI Plus Bevacizumab Versus FOLFOX Plus Bevacizumab Followed by FOLFIRI Plus Panitumumab in Wild-Type RAS Metastatic Colorectal Cancer
Registered drugNo placebo
Phase III Study Comparing FOLFOX Plus Panitumumab Followed by FOLFIRI Plus Bevacizumab Versus FOLFOX Plus Bevacizumab Followed by FOLFIRI Plus Panitumumab in Wild-Type RAS Metastatic Colorectal Cancer
Registered drugNo placebo
- Disease:Colorectal cancer metastatic
- Substances:BevacizumabFluorouracil+4
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Bevacizumab
- Sponsor:Asociacion Grupo Tratamiento De Tumores Digestivos
Not recruiting
Diffuse large B-cell lymphoma refractory
Not recruitingA study evaluating glofitamab and a drug combination for patients with relapsed or refractory diffuse large B-cell lymphoma.
Registered drugNo placebo
A study evaluating glofitamab and a drug combination for patients with relapsed or refractory diffuse large B-cell lymphoma.
Registered drugNo placebo
- Disease:Diffuse large B-cell lymphoma refractory
- Substances:GlofitamabObinutuzumab+2
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Glofitamab
- Sponsor:F. Hoffmann-La Roche AG
Other cities in Spain
The busiest research cities in the country
- Madrid3 294 trials · 24 research sites
- Barcelona3 147 trials · 23 research sites
- Valencia1 777 trials · 8 research sites
- Malaga1 052 trials · 4 research sites
- L'hospitalet De Llobregat978 trials · 4 research sites
- Badalona768 trials · 3 research sites
- Pamplona753 trials · 1 research site
- Santiago De Compostela682 trials · 3 research sites
Clinical research in Sevilla
What the registry says about research in the country
01 Metabolic and Endocrine Disorders
Innovative research focusing on Type 1 Diabetes management and weight-related conditions, evaluating new therapeutic approaches for glycemic control and metabolic health.
- Diabetes Management
- Obesity Treatment
- Metabolic Disorders
Studies aim to improve treatment outcomes for patients with complex metabolic conditions.
02 Neurological Conditions
Advanced clinical trials examining treatments for Multiple Sclerosis and neurodegenerative disorders, including pioneering research in Frontotemporal Dementia and Parkinson's disease.
- Multiple Sclerosis Therapies
- Neurodegenerative Diseases
- Brain Health Innovation
Research focuses on developing targeted treatments for various neurological conditions.
03 Infectious Diseases
Comprehensive vaccine development programs targeting Influenza, Cytomegalovirus, and meningococcal infections, with emphasis on preventive medicine.
- Vaccine Development
- Viral Infections
- Immunization Studies
Studies aim to enhance vaccine efficacy and immune response across different age groups.
04 Oncology Research
Groundbreaking studies in cancer treatment, including research on bladder cancer and mantle cell lymphoma, exploring combination therapies and targeted treatments.
- Cancer Immunotherapy
- Targeted Therapies
- Combination Treatments
Focus on developing innovative approaches to improve cancer treatment outcomes.
05 Autoimmune Conditions
Clinical investigations into Psoriatic Arthritis and inflammatory conditions, evaluating novel therapeutic approaches and treatment combinations.
- Arthritis Treatment
- Inflammatory Diseases
- Immune System Disorders
Research aims to develop more effective treatments for chronic autoimmune conditions.